enGene Holdings Statistics
Total Valuation
enGene Holdings has a market cap or net worth of $423.10 million. The enterprise value is $252.56 million.
Important Dates
The last earnings date was Thursday, September 11, 2025, after market close.
| Earnings Date | Sep 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
enGene Holdings has 51.19 million shares outstanding. The number of shares has increased by 83.91% in one year.
| Current Share Class | 51.19M |
| Shares Outstanding | 51.19M |
| Shares Change (YoY) | +83.91% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 0.87% |
| Owned by Institutions (%) | 33.51% |
| Float | 18.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.10 |
| P/TBV Ratio | 2.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.34, with a Debt / Equity ratio of 0.16.
| Current Ratio | 10.34 |
| Quick Ratio | 9.91 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -33.71 |
Financial Efficiency
Return on equity (ROE) is -43.95% and return on invested capital (ROIC) is -25.95%.
| Return on Equity (ROE) | -43.95% |
| Return on Assets (ROA) | -24.67% |
| Return on Invested Capital (ROIC) | -25.95% |
| Return on Capital Employed (ROCE) | -44.93% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.66M |
| Employee Count | 57 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, enGene Holdings has paid $516,000 in taxes.
| Income Tax | 516,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.21% in the last 52 weeks. The beta is -0.26, so enGene Holdings's price volatility has been lower than the market average.
| Beta (5Y) | -0.26 |
| 52-Week Price Change | -12.21% |
| 50-Day Moving Average | 6.45 |
| 200-Day Moving Average | 5.08 |
| Relative Strength Index (RSI) | 56.10 |
| Average Volume (20 Days) | 377,771 |
Short Selling Information
The latest short interest is 57,496, so 0.11% of the outstanding shares have been sold short.
| Short Interest | 57,496 |
| Short Previous Month | 37,357 |
| Short % of Shares Out | 0.11% |
| Short % of Float | 0.30% |
| Short Ratio (days to cover) | 0.15 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -101.14M |
| Pretax Income | -94.21M |
| Net Income | -94.72M |
| EBITDA | -100.95M |
| EBIT | -101.14M |
| Earnings Per Share (EPS) | -$1.92 |
Full Income Statement Balance Sheet
The company has $201.91 million in cash and $31.38 million in debt, giving a net cash position of $170.54 million or $3.33 per share.
| Cash & Cash Equivalents | 201.91M |
| Total Debt | 31.38M |
| Net Cash | 170.54M |
| Net Cash Per Share | $3.33 |
| Equity (Book Value) | 200.67M |
| Book Value Per Share | 3.93 |
| Working Capital | 190.87M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$93.85 million and capital expenditures -$1.29 million, giving a free cash flow of -$95.13 million.
| Operating Cash Flow | -93.85M |
| Capital Expenditures | -1.29M |
| Free Cash Flow | -95.13M |
| FCF Per Share | -$1.86 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
enGene Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -83.91% |
| Shareholder Yield | -83.91% |
| Earnings Yield | -22.39% |
| FCF Yield | -22.48% |
Analyst Forecast
The average price target for enGene Holdings is $20.29, which is 147.44% higher than the current price. The consensus rating is "Buy".
| Price Target | $20.29 |
| Price Target Difference | 147.44% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |